Skip to content
← All treatment topics

TREATMENT READING

Childhood Adrenocortical Carcinoma

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

For patients

Treatment options for children with adrenocortical carcinoma

Source: Childhood Adrenocortical Carcinoma, National Cancer Institute.

Source updated: January 12, 2024. Captured 2026-09-09.

Treatment options for children with adrenocortical carcinoma

There are different types of treatment for children with adrenocortical carcinoma.

Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment.

Sources: clinical trials · research study

Because cancer in children is rare, taking part in a clinical trial should be considered. Some clinical trials are open only to patients who have not started treatment.

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

For patients · Treatment options for children with adrenocortical carcinoma

Who treats children with adrenocortical carcinoma?

Source: Childhood Adrenocortical Carcinoma, National Cancer Institute.

Source updated: January 12, 2024. Captured 2026-09-09.

Treatment will be overseen by a pediatric oncologist, a doctor who specializes in treating children with cancer. The pediatric oncologist works with other pediatric health professionals who are experts in treating children with cancer and who specialize in certain areas of medicine. This may include the following specialists and others:

Pediatrician.

Sources: Pediatrician

Pediatric surgeon.

Sources: Pediatric surgeon

Radiation oncologist.

Sources: Radiation oncologist

Pathologist.

Sources: Pathologist

Endocrinologist.

Sources: Endocrinologist

Pediatric nurse specialist.

Sources: Pediatric nurse specialist

Social worker.

Sources: Social worker

Rehabilitation specialist.

Sources: Rehabilitation specialist

Psychologist.

Sources: Psychologist

Child-life specialist.

Sources: Child-life specialist

Two types of standard treatment are used:

For patients · Treatment options for children with adrenocortical carcinoma

Surgery

Source: Childhood Adrenocortical Carcinoma, National Cancer Institute.

Source updated: January 12, 2024. Captured 2026-09-09.

Surgery to remove the tumor is the main treatment for adrenocortical carcinoma.

Sources: Surgery

For patients · Treatment options for children with adrenocortical carcinoma

Chemotherapy

Source: Childhood Adrenocortical Carcinoma, National Cancer Institute.

Source updated: January 12, 2024. Captured 2026-09-09.

Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy).

Sources: Chemotherapy · drugs · cells · injected · vein · systemic chemotherapy

For patients · Treatment options for children with adrenocortical carcinoma

New treatments being tested in clinical trials

Source: Childhood Adrenocortical Carcinoma, National Cancer Institute.

Source updated: January 12, 2024. Captured 2026-09-09.

This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the NCI website.

Sources: clinical trials · NCI website

For patients · Treatment options for children with adrenocortical carcinoma / New treatments being tested in clinical trials

Immunotherapy

Source: Childhood Adrenocortical Carcinoma, National Cancer Institute.

Source updated: January 12, 2024. Captured 2026-09-09.

Immunotherapy is a treatment that uses the patient’s immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body’s natural defenses against cancer.

Sources: Immunotherapy · immune system

Immune checkpoint inhibitor therapy is a type of immunotherapy that blocks certain proteins. PD-1 is a protein on the surface of T cells that helps keep the body’s immune responses in check. PD-L1 is a protein found on some types of cancer cells. When PD-1 attaches to PD-L1, it stops the T cell from killing the cancer cell. PD-1 and PD-L1 inhibitors keep PD-1 and PD-L1 proteins from attaching to each other. This allows the T cells to kill cancer cells. Pembrolizumab is a PD-1 inhibitor that is being studied in the treatment of childhood adrenocortical carcinoma that is advanced or has come back after treatment.

Sources: Immune checkpoint inhibitor · proteins · PD-1 · T cells · immune responses · PD-L1 · Pembrolizumab · advanced

For patients

Treatment of newly diagnosed childhood adrenocortical carcinoma

Source: Childhood Adrenocortical Carcinoma, National Cancer Institute.

Source updated: January 12, 2024. Captured 2026-09-09.

Treatment of newly diagnosed childhood adrenocortical carcinoma

Treatment of newly diagnosed adrenocortical carcinoma in children may include the following:

Surgery to remove the adrenal gland and, if needed, cancer that has spread to other parts of the body. Sometimes chemotherapy is also given.

Sources: Surgery · adrenal gland · chemotherapy

For patients

Treatment of recurrent childhood adrenocortical carcinoma

Source: Childhood Adrenocortical Carcinoma, National Cancer Institute.

Source updated: January 12, 2024. Captured 2026-09-09.

Treatment of recurrent childhood adrenocortical carcinoma

Treatment of recurrent adrenocortical carcinoma in children may include the following:

Sources: recurrent

A clinical trial of an immune checkpoint inhibitor.

Sources: clinical trial · immune checkpoint inhibitor

For patients · Clinical trials

Patients can enter clinical trials before, during, or after starting their cancer treatment

Source: Childhood Adrenocortical Carcinoma, National Cancer Institute.

Source updated: January 12, 2024. Captured 2026-09-09.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.

Sources: side effects

Clinical trials are taking place in many parts of the country. Find clinical trials for adrenocortical carcinoma at Treatment Clinical Trials for Adrenal Cortex Cancer. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website. General information about clinical trials is also available.

Sources: Treatment Clinical Trials for Adrenal Cortex Cancer · ClinicalTrials.gov · General information

For patients

Side effects of treatment

Source: Childhood Adrenocortical Carcinoma, National Cancer Institute.

Source updated: January 12, 2024. Captured 2026-09-09.

Side effects of treatment

To learn more about side effects that begin during treatment for cancer, visit Side Effects.

Sources: side effects · Side Effects

Side effects from cancer treatment that begin after treatment and continue for months or years are called late effects. Late effects of cancer treatment may include the following:

Sources: late effects

Physical problems, including problems with the thyroid gland, hearing, fully opening the mouth, dental cavities, and chronic sinusitis or ear infections.

Sources: thyroid gland · cavities · sinusitis · infections

Changes in mood, feelings, thinking, learning, or memory.

Second cancers (new types of cancer) or other conditions.

Sources: conditions

Some late effects may be treated or controlled. It is important to talk with your child's doctors about the possible late effects caused by some treatments. See the PDQ summary on Late Effects of Treatment for Childhood Cancer for more information.

Sources: Late Effects of Treatment for Childhood Cancer

Health professional

Special Considerations for the Treatment of Children With Cancer

Source: Childhood Adrenocortical Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:

Sources: 1

Primary care physicians.

Pediatric surgeons.

Pathologists.

Pediatric radiation oncologists.

Pediatric medical oncologists and hematologists.

Ophthalmologists.

Rehabilitation specialists.

Pediatric oncology nurses.

Social workers.

Child-life professionals.

Psychologists.

Nutritionists.

For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.

Sources: Supportive and Palliative Care

The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.

Sources: 2 · NCI website

Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[3-5] Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment. For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.

Sources: 3 · 5 · Late Effects of Treatment for Childhood Cancer

Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.[6] The U.S. Rare Diseases Act of 2002 defines a rare disease as one that affects populations smaller than 200,000 people in the United States. Therefore, all pediatric cancers are considered rare.

Sources: 6 · Rare Diseases Act of 2002

The designation of a rare tumor is not uniform among pediatric and adult groups. In adults, rare cancers are defined as those with an annual incidence of fewer than six cases per 100,000 people. They account for up to 24% of all cancers diagnosed in the European Union and about 20% of all cancers diagnosed in the United States.[7,8] In children and adolescents, the designation of a rare tumor is not uniform among international groups, as follows:

Sources: 7 · 8

A consensus effort between the European Union Joint Action on Rare Cancers and the European Cooperative Study Group for Rare Pediatric Cancers estimated that 11% of all cancers in patients younger than 20 years could be categorized as very rare. This consensus group defined very rare cancers as those with annual incidences of fewer than two cases per 1 million people. However, three additional histologies (thyroid carcinoma, melanoma, and testicular cancer) with incidences of more than two cases per 1 million people were also included in the very rare group due to a lack of knowledge and expertise in the management of these tumors.[9]

Sources: 9

The Children's Oncology Group defines rare pediatric cancers as those listed in the International Classification of Childhood Cancer subgroup XI, which includes thyroid cancers, melanomas and nonmelanoma skin cancers, and multiple types of carcinomas (e.g., adrenocortical carcinomas, nasopharyngeal carcinomas, and most adult-type carcinomas such as breast cancers and colorectal cancers).[10] These diagnoses account for about 5% of the cancers diagnosed in children aged 0 to 14 years and about 27% of the cancers diagnosed in adolescents aged 15 to 19 years.[4] Most cancers in subgroup XI are either melanomas or thyroid cancers, with other cancer types accounting for only 2% of the cancers diagnosed in children aged 0 to 14 years and 9.3% of the cancers diagnosed in adolescents aged 15 to 19 years.

Sources: 10 · 4

These rare cancers are extremely challenging to study because of the relatively few patients with any individual diagnosis, the predominance of rare cancers in the adolescent population, and the small number of clinical trials for adolescents with rare cancers.

Information about these tumors may also be found in sources relevant to adults with cancer, such as Adrenocortical Carcinoma Treatment.

Sources: Adrenocortical Carcinoma Treatment

Health professional

Treatment of Childhood Adrenocortical Carcinoma

Source: Childhood Adrenocortical Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

At the time of diagnosis, two-thirds of pediatric patients have limited disease (tumors that can be completely resected), and the remaining patients have either unresectable or metastatic disease.[1]

Sources: 1

The European Cooperative Study Group for Pediatric Rare Tumors within the PARTNER project (Paediatric Rare Tumours Network - European Registry) has published consensus guidelines for the diagnosis and treatment of childhood adrenocortical tumors.[2] Treatment of childhood adrenocortical tumors has evolved using the data from adult studies, and the same guidelines are used. Surgery is the most important mode of therapy, and mitotane and cisplatin-based regimens, usually incorporating doxorubicin and etoposide, are recommended for patients with advanced disease.[3-6]; [7][Level of evidence C1]

Sources: 2 · 3 · 6 · 7 · Level of evidence C1

Treatment options for childhood adrenocortical tumors include the following:

Surgery with or without adjuvant chemotherapy.

Sources: Surgery · chemotherapy

Health professional · Treatment of Childhood Adrenocortical Carcinoma

Surgery

Source: Childhood Adrenocortical Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

An aggressive surgical approach toward the primary tumor and all metastatic sites is recommended when feasible.[8,9] Because of tumor friability, rupture of the capsule with resultant tumor spillage is frequent (approximately 20% of initial resections and 43% of resections after recurrence).[1] When the diagnosis of adrenocortical tumor is suspected, laparotomy and a curative procedure are recommended rather than fine-needle aspiration to avoid the risk of tumor rupture.[9,10] Laparoscopic resection is associated with a high risk of rupture and peritoneal carcinomatosis. Therefore, open adrenalectomy remains the standard of care.[11]

Sources: 8 · 9 · 1 · 9 · 10 · 11

Evidence (surgery):

The Children's Oncology Group conducted a prospective, single-arm, risk-stratified, interventional study between 2006 and 2013 (ARAR0332 [NCT00304070]).[12][Level of evidence B4] Patients with stage I disease had small tumors limited to the adrenal gland and were treated with adrenalectomy alone. Patients with stage II disease had tumors larger than 200 mL or heavier than 100 g and were treated with adrenalectomy and retroperitoneal lymph node dissection (RPLND). Patients with stage III disease had incompletely resected primary tumors. Patients with stage IV disease had distant metastatic disease. Patients with stage III and stage IV disease were treated with surgery of the primary tumor, RPLND, cisplatin, etoposide, doxorubicin, and mitotane.The stated goal of the study was to determine if RPLND would improve outcomes for patients with stage II disease. The operative notes to assess the adequacy of the RPLND were available for 11 of 15 patients. The median number of lymph nodes resected was 4 (range, 1–30). In a multivariable analysis performed in a cohort of 283 adult patients with adrenocortical carcinoma, patients who underwent RPLND (defined as >5 nodes resected) had a significantly reduced recurrence risk and disease-related death rate than patients who did not undergo nodal dissection.[13] The authors speculate that the RPLNDs performed in this study may not have been as thorough as the procedures carried out in the adult series, which could confound conclusions about the potential value of RPLND.

Sources: ARAR0332 [NCT00304070] · 12 · Level of evidence B4 · 13

The Children's Oncology Group conducted a prospective, single-arm, risk-stratified, interventional study between 2006 and 2013 (ARAR0332 [NCT00304070]).[12][Level of evidence B4] Patients with stage I disease had small tumors limited to the adrenal gland and were treated with adrenalectomy alone. Patients with stage II disease had tumors larger than 200 mL or heavier than 100 g and were treated with adrenalectomy and retroperitoneal lymph node dissection (RPLND). Patients with stage III disease had incompletely resected primary tumors. Patients with stage IV disease had distant metastatic disease. Patients with stage III and stage IV disease were treated with surgery of the primary tumor, RPLND, cisplatin, etoposide, doxorubicin, and mitotane.The stated goal of the study was to determine if RPLND would improve outcomes for patients with stage II disease. The operative notes to assess the adequacy of the RPLND were available for 11 of 15 patients. The median number of lymph nodes resected was 4 (range, 1–30). In a multivariable analysis performed in a cohort of 283 adult patients with adrenocortical carcinoma, patients who underwent RPLND (defined as >5 nodes resected) had a significantly reduced recurrence risk and disease-related death rate than patients who did not undergo nodal dissection.[13] The authors speculate that the RPLNDs performed in this study may not have been as thorough as the procedures carried out in the adult series, which could confound conclusions about the potential value of RPLND.

The 5-year event-free survival rate estimates were 86.2% for patients with stage I disease (n = 24), 53.3% for patients with stage II disease (n = 15), 81% for patients with stage III disease (n = 24), and 7.1% for patients with stage IV disease (n = 14).

On multivariable analysis, only stage and age were significantly associated with outcome.

The authors reported that the combination of mitotane and chemotherapy resulted in significant toxicity. One-third of patients with advanced disease could not complete the scheduled treatment.

Health professional · Treatment of Childhood Adrenocortical Carcinoma

Chemotherapy

Source: Childhood Adrenocortical Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Little information is available about the use of mitotane in children, although response rates appear to be similar to those seen in adults.[4,14] In adults, mitotane is commonly used as a single agent in the adjuvant setting after complete resection.[4]

Sources: 4 · 14 · 4

Evidence (surgery and chemotherapy):

One review included 11 children with advanced adrenocortical tumors who were treated with a mitotane and cisplatin-based chemotherapeutic regimen.[4]

Sources: 4

One review included 11 children with advanced adrenocortical tumors who were treated with a mitotane and cisplatin-based chemotherapeutic regimen.[4]

Measurable responses were seen in seven patients.

The mitotane daily dose required for therapeutic levels was approximately 4 g/m2, and therapeutic levels were achieved after 4 to 6 months of therapy.

In the GPOH-MET 97 trial, mitotane levels greater than 14 mg/L correlated with better survival in children.[6,7]

Sources: 6 · 7

A retrospective analysis identified 177 Italian and German adult patients with completely resected adrenocortical carcinoma.[15] For more information, see Adrenocortical Carcinoma Treatment.

Sources: 15 · Adrenocortical Carcinoma Treatment

A retrospective analysis identified 177 Italian and German adult patients with completely resected adrenocortical carcinoma.[15] For more information, see Adrenocortical Carcinoma Treatment.

Recurrence-free survival was significantly prolonged by the use of adjuvant mitotane.

The benefit was present with 1 to 3 g per day of mitotane, and this dose was associated with fewer toxic side effects than doses of 3 to 5 g per day.

Adrenocortical tumors are generally considered to be radioresistant. The use of radiation therapy in pediatric patients with adrenocortical tumors has not been consistently investigated. Furthermore, because many children with adrenocortical tumors carry germline TP53 pathogenic variants that predispose them to cancer, radiation may increase the incidence of secondary tumors. One study reported that three of five long-term survivors of pediatric adrenocortical tumors died of secondary sarcomas that arose within the radiation field.[6,16]

Sources: 6 · 16

For more information, see Adrenocortical Carcinoma Treatment.

Sources: Adrenocortical Carcinoma Treatment

Health professional

Treatment of Relapsed Childhood Adrenocortical Carcinoma

Source: Childhood Adrenocortical Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Treatment options for relapsed childhood adrenocortical tumors include the following:

Checkpoint inhibitors. In a phase I/II trial of pediatric patients with advanced or relapsed solid tumors who were treated with pembrolizumab, two of four patients with adrenocortical carcinomas achieved partial responses.[1]

Sources: 1

Tyrosine kinase inhibitors. A single-arm phase II trial included patients aged 18 years and older who had adrenocortical carcinoma and were not candidates for surgery with curative intent. The administration of cabozantinib was associated with stable disease in 12 of 16 patients, for a median duration of 3.7 months, and confirmed partial responses in 2 patients.[2]

Sources: 2

Health professional

Treatment Options Under Clinical Evaluation for Childhood Adrenocortical Carcinoma

Source: Childhood Adrenocortical Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

Studies

Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

NCT00304070 · COMPLETED · phase3

Stage I Adrenal Cortical Carcinoma AJCC v7, Stage II Adrenal Cortical Carcinoma AJCC v7, Stage III Adrenal Cortical Carcinoma AJCC v7, Stage IV Adrenal Cortical Carcinoma AJCC v7

ClinicalTrials.gov record

Disease and treatment settings

Childhood Adrenocortical Carcinoma

Disease and treatment setting

Adrenocortical Carcinoma in children and adolescents

Childhood Adrenocortical Carcinoma

Disease and treatment setting

Treatment of newly diagnosed childhood adrenocortical carcinoma

recurrent Childhood Adrenocortical Carcinoma

Disease and treatment setting

Treatment of recurrent childhood adrenocortical carcinoma